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Abstract: Backround: Statin treatment is considered as first line therapy in patients with atherosclerotic disease. We 
evaluated the effect of pre-treatment with statins on carotid plaque infiltration by macrophages and on the circulating lev-
els of proinflammatory cytokines in patients who underwent carotid endarterectomy. 
Patients and Methods: One hundred fourteen patients were enrolled; 89 men and 25 women (mean age 67±8 years; range 
42-83 years). Fifty three patients (46%) were on statin treatment at least 3 months before endarterectomy and 61 (54%) 
had never received statin treatment. The serum levels of high sensitivity C reactive protein (hsCRP), serum amyloid A 
(SAA), tumor necrosis factor  (TNF), interleukin (IL)-1 and IL-6 were evaluated preoperatively. The intensity of 
macrophage infiltration was evaluated by immunochemistry, using the monoclonal antibody CD 68. The area of the 
plaque covered by macrophages was measured as a proportion of the whole plaque area, using a custom designed image 
tool analysis. 
Results: Patients on statins had lower serum total cholesterol levels (172±50 vs 194±35 mg/dl, p= 0.014), lower low den-
sity cholesterol levels (103±44 vs 123±31 mg/dl, p= 0.010) and lower serum hsCRP levels (1.8 [1.1-3.4] vs 3.4 [1.3-4.9] 
mg/l, p= 0.03), while SAA, TNF, IL-6 and IL-1 levels did not differ between the 2 groups. The infiltration of atheroscle-
rotic plaque by macrophages was similar in statin treated patients and in controls (0.55±0.15% vs 0.49±0.19%, p= 0.21).  
Conclusion: Patients on statins have similar macrophage accumulation in their carotid atherosclerotic plaques compared 
with patients not on statins. Inflammatory markers were also similar in both groups except for hsCRP which was signifi-
cantly lower in those taking statins.  
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INTRODUCTION 
The relationship between atherosclerosis and inflamma-
tion is well established [1-3]. Inflammation plays a role in 
plaque formation; even “early atherosclerosis”, fatty streaks, 
consists of macrophage accumulation [4]. Inflammation also 
has a role in plaque destabilization and rupture [5,6] since 
macrophages and other inflammatory molecules are in-
creased in symptomatic plaques [7].  
Treatment with statins is considered as first line therapy 
in atherosclerotic disease [8-15]. Statins also exert anti-
inflammatory effects [9-17].  
The aim of this study was to evaluate the inflammatory 
burden in human carotid artery specimens as well as circulat-
ing inflammatory marker levels, in patients on statins and 
those not receiving these drugs. 
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PATIENTS AND METHODS  
We evaluated patients who underwent carotid endarterec-
tomy for significant (>70%) carotid bifurcation stenosis. The 
degree of stenosis was calculated using Digital Subtraction 
Angiography and the North America Symptomatic Carotid 
Endarterectomy Collaborators study [18] criteria of evalua-
tion and measurement of carotid artery stenosis. The criteria 
for patient selection have been described [19]. 
All patients underwent a computerized tomographic brain 
study and were examined by the same neurologists. Based on 
data from history and clinical examination the patients were 
characterized as symptomatic or asymptomatic. Patients with 
amaurosis fugax, transient ischemic cerebral symptoms or 
ipsilateral ischemic stroke were characterized as sympto-
matic. The remaining patients were characterized as asymp-
tomatic.  
Initially, 119 patients scheduled to undergo carotid en-
darterectomy were evaluated. Five patients that began statin 
therapy less than 3 months before endarterectomy were ex-
cluded from the study. The remaining 114 consecutive pa-Statins and Plaque Inflammation  The Open Cardiovascular Medicine Journal, 2008, Volume 2    111 
tients formed the study population. Fifty three (46%) of them 
were on statin therapy at least 3 months before endarterec-
tomy. The other 61 (54%) patients had never received stat-
ins. The following statins were used: 26 (47%) patients were 
on atorvastatin (22±11 mg/day), 16 (29%) on simvastatin 
(27±10 mg/day), 8 (15%) on pravastatin (30±12 mg/day), 2 
(4%) on lovastatin (20 mg/day) and 1 (2%) was on fluvas-
tatin (20 mg/day).  
The study protocol was approved by the Red Cross Hos-
pital Ethical Committee. Informed consent was obtained 
from all patients.  
LABORATORY ANALYSIS  
Blood samples were obtained from all patients the day 
before endarterectomy, after an overnight fast. The samples 
were centrifuged for 15 min at approximately 1000 g. Serum 
was removed, aliquoted immediately and stored at -70° C 
until tested. Part of the blood sample was used to measure 
common serum parameters and the lipid profile. Serum inter-
leukin (IL)-1, IL-6 and tumor necrosis factor- (TNF) 
concentrations were measured using quantitative sandwich 
enzyme immunoassay kits (Quantikine HS, R&D Systems, 
Minneapolis, USA). The lower limit of detection was <0.1 
pg/ml for IL-1, 0.04 pg/ml for IL-6 and 0.12 pg/ml for 
TNF; high sensitivity C-reactive protein (hsCRP) and se-
rum amyloid A (SAA) were assayed by high sensitivity par-
ticle enhanced immunonephelometry (N Latex, Date-
Behring Marburg GmbH, Marburg, Germany). The lower 
limit of detection was 0.18 mg/l for hsCRP and 0.8 mg/l for 
SAA. Values below the lower detection limit were consid-
ered as equal with this limit in the statistical analysis; there 
were no missing values. The coefficient variations for the 
assays used were for IL-1, IL-6, TNF, hsCRP and SAA 
14%, 11%, 22%, 6% and 12%, respectively. Homocysteine 
levels were determined using an enzymatic assay for the 
Hitachi 917 analyzer (Roche Diagnostics, Indianapolis, IN 
46250, USA), as previously described [20]. 
CAROTID ENDARTERECTOMY 
All carotid endarterectomy procedures were performed 
by 1 group of vascular surgeons at the Department of Vascu-
lar Surgery of the Red Cross Hospital in Athens, from June 
2004 to May 2006. Immediately after carotid endarterectomy 
the specimen was transferred in 0.9% normal saline solution 
to the laboratory. Transverse sections 4 mm thick were pre-
pared from each atherosclerotic lesion. The section contain-
ing the most stenotic part of the bifurcation was labelled 0, 
while the consecutive parts distally were labelled +1, +2, +3 
etc and proximally -1, -2, -3 etc. Each part was embedded in 
a different paraffin block. Sequential transverse sections 4 
μm apart were obtained from each block and stained with 
haematoxylin and eosin. These sections were used for classi-
fication of the atherosclerotic plaque according to the 
American Heart Association (AHA) criteria [4].  
IMMUNOHISTOCHEMISTRY 
In order to measure macrophage infiltration of athero-
sclerotic plaques, we used monoclonal antibodies to a cell 
marker (CD68, Q-Bend Clone, Dako Corporation, Caprinte-
ria, California, USA). Sequential sections 4 mm apart were 
evaluated from the atherosclerotic part of each specimen. 
The number of slides evaluated per patient was 4.1±2.4 
(mean±SD). The whole plaque area, excluding parts of the 
specimen without obvious atherosclerotic lesions, was 
evaluated at x400 magnification. Evaluation of the images 
was performed with the Image Tool analysis system (Image 
Pro Plus, Media Software, Cybernetics, Canada) by 2 inde-
pendent examiners blinded to the clinical history, and the 
mean value was recorded. The results were expressed as the 
proportion of the whole plaque area stained with the mono-
clonal antibody CD 68. 
STATISTICAL ANALYSIS 
Continuous parameters are reported as mean ± standard 
deviation, non parametric variables as median (interquartile 
interval) and categorical variables as percentages. The t-test 
or Mann-Whitney test was used for comparing continuous 
variables between 2 groups, as appropriate. Categorical vari-
ables were compared by the chi-square test or Fisher’s exact 
test. The Spearman correlation test was used to assess rela-
tionships between variables. A p<0.05 was considered sig-
nificant. 
RESULTS 
Clinical and demographic characteristics of the study 
population are shown in Table 1. Statin treated patients had 
lower serum total cholesterol (176±49 vs 202±40 mg/dl,   
p= 0.011) and low density lipoprotein cholesterol (LDL-C 
103±46 vs 127±34 mg/dl, p<0.001) than patients not receiv-
ing these drugs. The 2 groups had no differences in AHA 
plaque classification and in procedural complications (data 
not shown). 
hsCRP serum levels were significantly lower in patients 
on statins than in the controls (Table 2). The serum levels of 
SAA, TNF, IL-1 and IL-6 did not differ between the 2 
study groups (Table 2).  
Patients on statin treatment had no differences in the le-
sion area covered by macrophages compared with patients 
not receiving these drugs (0.55±0.15% vs 0.49±0.19%,   
p= 0.21, data not shown). The interobeserver variability was 
moderate (= 0.61±0.09). 
DISCUSSION 
The main finding of this study is that patients on statins 
had the same degree of macrophage infiltration of their ca-
rotid atherosclerotic plaque with patients not receiving these 
drugs although serum hsCRP levels were significantly lower.  
Several, but not all, studies favour the hypothesis that 
statins have beneficial effect on macrophage accumulation. 
Tahara et al. [21] using fluorodeoxyglucose positron emis-
sion tomography reported that simvastatin reduces the num-
ber of inflammation-rich atherosclerotic plaques compared 
with a placebo group. Crisby et al. [22] reported that patients 
pre-treated with pravastatin had less inflammation in their 
carotid arteries, compared with patients on placebo. Similar 
results were reported in monkeys, using simvastatin or 
pravastatin [23]. On the other hand, Verhoeven et al. [24] 
demonstrated that statin treated patients have increased 
amount of macrophages in their carotid endarterectomy 
specimens. However, in patients treated with atorvastatin, 
the increased amount of CD68 positive cells was not associ-
ated with increased protease activity [24]. Our findings are 
not consistent with either of these hypotheses, since we did 112    The Open Cardiovascular Medicine Journal, 2008, Volume 2  Koutouzis et al. 
not demonstrate any difference in macrophage infiltration 
between patients receiving statins and those not on these 
drugs.  
hsCRP was lower in patients treated with statins, while 
the levels of SAA, TNF, IL-1 and IL-6 were not different 
between the 2 groups. Statin-induced reduction in hsCRP 
Table 1.  Clinical and Demographic Characteristics of the Statin and Control Groups  
  Statin Group  Control Group   p 
n 53  61   
Age (years)  65.7 ± 9.0  67.0 ± 8.3  0.40 
Duration of statin treatment (months)  20 ± 17     
Cardiovascular risk factors 
Male sex  42 (79%)  45 (74%)  0.64 
Coronary artery disease  13 (25%)  6 (10%)  0.07 
Arterial Hypertension  39 (74%)  49 (80%)  0.53 
Diabetes mellitus  15 (28%)  14 (23%)  0.66 
Current cigarette smoking  31 (58%)   38 (62%)  0.82 
Medical treatment 
ACE inhibitors   22 (41%)  22 (36%)  0.69 
ARBs  10 (19%)  13 (21%)  0.93 
Beta-blockers   18 (38%)  14 (23%)  0.27 
Calcium channel blockers   15 (34%)  27 (44%)  0.12 
Diuretics   10 (19%)  21 (34%)  0.08 
Clopidogrel   22 (42%)  24 (39%)  0.91 
Aspirin   23 (43%)  29 (48%)  0.67 
Diabetes mellitus (oral drugs)   12 (22%)  10 (16%)  0.61 
Diabetes mellitus (insulin)  2 (4%)  3 (5%)  0.91 
Presence/absence of symptoms 
Symptomatic  28 (53%)  31 (51%)  0.86 
Amaurosis Fugax  1 (2%)   2 (3%)  0.93 
Transient Ischemic Attacks  22 (42%)  23 (38%)  0.95 
Ischemic Stroke  5 (9%)  6 (10%)  0.86 
Asymptomatic  25 (47%)  32 (52%)  0.57 
Serum parameters 
Total Cholesterol (mg/dl)  176 ± 49  202 ± 40  0.011 
Low-density lipoprotein (mg/dl)  103 ± 46  127 ± 34  <0.001 
High-density lipoprotein (mg/dl)  38 ± 6  42 ± 10  0.16 
Triglyceride (mg/dl)  159 ± 109  154 ± 66  0.86 
Apolipoprotein A (mg/dl)  111 ± 21  118 ± 24  0.23 
Apolipoprotein B (mg/dl)  89 ± 30  96 ± 26  0.11 
Lipoprotein (a) (mg/dl)  48 ± 52  41 ± 29  0.87 
Homocysteine (μmol/l)  10.4 ± 3.7  13.0 ± 5.1  0.07 
Creatinine (mg/dl)  1.00 ± 0.44  1.03 ± 0.47  0.58 
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levels have been demonstrated in many studies in different 
patient populations [25-28]. The same is also true for SAA 
[29] although we did not observe this effect.  
Statins are potent anti-inflammatory agents [2, 30-34]. 
The effect of statins on levels of inflammatory markers was 
evaluated in a group of hypercholesterolemic patients (n=68) 
[35]. Compared with diet alone, an 8-week regimen with 
atorvastatin plus diet recommendation was associated with a 
significant reduction in plasma levels of TNF (2.9% vs 
21.4%, respectively; p<0.0001), IL-6 (2.0% vs 22.1%, re-
spectively; p<0.0001) and IL-1 (2.7% vs 16.4%, respectively; 
p<0.0001) [35]. A similar association between statin use and 
reduction of TNF and IL-10 plasma levels was recently 
reported in patients with calcific aortic valve stenosis [36].  
STUDY LIMITATIONS 
This was a prospective cross sectional study comparing 
patients receiving statins for more than 3 months with pa-
tients who never received these drugs. The different statins, 
with varying dosage and treatment duration is a limitation. 
The possible effect of other drugs (like angiotensin convert-
ing enzyme inhibitors, angiotensin receptor blockers, beta-
blockers and others) on macrophage accumulation also needs 
to be considered. The antibody CD68 used to validate 
macrophages is a non-selective macrophage marker and can-
not express the complicated functional status of the macro-
phages [24]. We also do not know if more aggressive LDL-C 
lowering would change the results.  
CONCLUSIONS 
Patients on statins have no differences in macrophage ac-
cumulation in carotid atherosclerotic plaques compared with 
patients who never took these drugs. Inflammatory markers 
were similar in both groups except for hsCRP which was 
significantly lower in those individuals taking statins.  
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